Enanta Pharmaceuticals (ENTA)
(Delayed Data from NSDQ)
$11.28 USD
-0.02 (-0.18%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $11.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Enanta Pharmaceuticals (ENTA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$16.83 | $27.00 | $10.00 | 48.94% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Enanta Pharmaceuticals comes to $16.83. The forecasts range from a low of $10.00 to a high of $27.00. The average price target represents an increase of 48.94% from the last closing price of $11.30.
Analyst Price Targets (6 )
Broker Rating
Enanta Pharmaceuticals currently has an average brokerage recommendation (ABR) of 2.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 2.43 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, three are Strong Buy, representing 42.86% of all recommendations. A month ago, Strong Buy represented 42.86%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.43 | 2.43 | 2.43 | 2.67 | 2.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | Not Identified | Not Identified | Hold | Hold |
8/6/2024 | Evercore Partners | Liisa A Bayko | Not Available | Strong Buy |
8/6/2024 | H.C. Wainwright & Co. | Ed Arce | Strong Buy | Strong Buy |
5/7/2024 | JMP Securities | Roy Buchanan | Strong Buy | Strong Buy |
5/6/2024 | SVB Securities | Roanna Ruiz | Hold | Hold |
2/7/2024 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.43 |
ABR (Last week) | 2.43 |
# of Recs in ABR | 7 |
Average Target Price | $18.71 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | -1.16 |
ENTA FAQs
Enanta Pharmaceuticals, Inc. (ENTA) currently has an average brokerage recommendation (ABR) of 2.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 7 brokerage firms.
The average price target for Enanta Pharmaceuticals, Inc. (ENTA) is $18.71. The current on short-term price targets is based on 4 reports.
The forecasts for Enanta Pharmaceuticals, Inc. (ENTA) range from a low of $10 to a high of $30. The average price target represents a increase of $65.87 from the last closing price of $11.28.
The current UPSIDE for Enanta Pharmaceuticals, Inc. (ENTA) is 65.87%
Based on short-term price targets offered by six analysts, the average price target for Enanta Pharmaceuticals comes to $16.83. The forecasts range from a low of $10.00 to a high of $27.00. The average price target represents an increase of 48.94% from the last closing price of $11.30.